CONTROLLED SUBSTANCES ACT
Amendments
Death and dying: promote pain management and palliative care without permitting assisted suicide and euthanasia (H.R. 2260), H10889, H10890, H10891 [27OC]
Drugs: treatment of gamma y-hydroxybutyrate and ketamine hydrochloride relative to the Controlled Substances Act (S. 1561), S14872, S15120 [19NO]
Analyses
Date-Rape Drug Control Act (S. 1561), S10486 [5AU]
Articles and editorials
Don't Kill the Pain-Relief Bill, S14776 [18NO]
Kill the Pain, Not the Patients—Congress Should Allow Doctors To Use Controlled Drugs for Aggressive Pain Treatment Instead of Suicide, S14777 [18NO]
Suicide Bill's Deep Flaws, H10882 [27OC]
Bills and resolutions
Courts: civil liability for illegal manufacturers and distributors of controlled substances (see H.R. 1042), H1069 [9MR]
Death and dying: promote pain management and palliative care without permitting assisted suicide and euthanasia (see S. 1272), S7527 [23JN] (see H.R. 2260), H4615 [17JN]
———promote pain management and palliative care without permitting assisted suicide and euthanasia (H.R. 2260), consideration (see H. Res. 339), H10723 [21OC]
Drugs: assess the abuse and trafficking of gamma hydroxybutyric acid and other controlled substances and drugs (see S. 1947), S14696 [17NO]
———combat manufacture, traffic, import, and export of amphetamine and methamphetamine (see S. 1428), S9073 [22JY]
———provide penalties for open air drug markets (see H.R. 342), H268 [19JA]
———registration requirements for practitioners who dispense narcotic drugs for maintenance or detoxification treatment (see S. 324), S1076 [28JA] (see H.R. 2634), H6598 [29JY]
———reschedule drugs that pose an imminent danger to public safety such as the date-rape drug, Rohpynol, and the ``club'' drug ketamine hydrochloride known as ``Special K'' (see S. 883), S4256 [27AP]
———treatment of gamma hydroxybutyric acid relative to the Controlled Substances Act (see H.R. 3457), H12791 [18NO]
———treatment of gamma y-hydroxybutyrate and ketamine hydrochloride relative to the Controlled Substances (see S. 1561), S10390 [5AU]
———treatment of gamma y-hydroxybutyrate and ketamine hydrochloride relative to the Controlled Substances Act (see H.R. 75), H233 [7JA] (see H.R. 1065), H1162 [10MR] (see H.R. 2130), H4127 [10JN]
Essays
While You Were Sleeping. . . (AKA—The Truth About Gamma Hydroxy Butyrate): Trinka Porrata, H9870 [12OC]
Letters
Date-Rape Drug Control Act: Judi Clark, S14874, S14875 [19NO]
———Trinka D. Porrata, S14874 [19NO]
Date-Rape Prevention Drug Act: Catherine H. Shaw, DEA, H9870 [12OC]
Drug Addiction Treatment Act: Alan I. Leshner, Dept. of HHS, S1091 [28JA]
Pain Relief Promotion Act: John B. Neeld, Jr., American Society of Anesthesiologists, S7534 [23JN]
———Karen A. Davie, National Hospice Organization, S7534 [23JN]
———Richard Payne, H10881 [27OC]
———Richard S. Weiner, American Academy of Pain Management, S7534 [23JN]
———Robert Raben, Dept. of Justice, H10883 [27OC]
Memorandums
Drug Addiction Treatment Act: Donald R. Wesson, American Society of Addiction Medicine, S1092 [28JA]
Motions
Death and dying: promote pain management and palliative care without permitting assisted suicide and euthanasia (H.R. 2260), H10898, H10902 [27OC]
Press releases
Pain Relief Promotion Act: American Pain Foundation, H10882 [27OC]
Remarks in House
Courts: civil liability for illegal manufacturers and distributors of controlled substances, H4442-H4445 [16JN]
Death and dying: promote pain management and palliative care without permitting assisted suicide and euthanasia (H.R. 2260), H8103 [13SE], H10121 [18OC], H10727, H10729 [25OC], H10864, H10876-H10903 [27OC], E2179 [25OC]
———promote pain management and palliative care without permitting assisted suicide and euthanasia (H.R. 2260), consideration (H. Res. 339), H10868-H10876 [27OC]
———promote pain management and palliative care without permitting assisted suicide and euthanasia (H.R. 2260), motion to recommit, H10902 [27OC]
———use of controlled substances by physicians, H10890, H10891 [27OC]
Drugs: treatment of gamma y-hydroxybutyrate and ketamine hydrochloride relative to the Controlled Substances Act (H.R. 2130), H9863-H9872, H9879 [12OC]
———treatment of gamma y-hydroxybutyrate and ketamine hydrochloride relative to the Controlled Substances Act (H.R. 75), H1024 [9MR], H1303 [16MR], H1338 [17MR], H1410 [18MR], H1599 [24MR]
Remarks in Senate
Death and dying: promote pain management and palliative care without permitting assisted suicide and euthanasia (H.R. 2260), S13156 [26OC]
———promote pain management and palliative care without permitting assisted suicide and euthanasia (S. 1272), S7532-S7534 [23JN], S7830 [29JN], S14774-S14777 [18NO]
Drugs: abuse of gamma y-hydroxybutyrate (GHB), S3824 [19AP]
———combat manufacture, traffic, import, and export of amphetamine and methamphetamine (S. 1428), S9087-S9093 [22JY]
———registration requirements for practitioners who dispense narcotic drugs for maintenance or detoxification treatment (S. 324), S1089-S1093 [28JA], S14940, S14942 [19NO]
———reschedule drugs that pose an imminent danger to public safety such as the date-rape drug, Rohpynol, and the ``club'' drug ketamine hydrochloride known as ``Special K'' (S. 883), S4272 [27AP]
———treatment of gamma y-hydroxybutyrate and ketamine hydrochloride relative to the Controlled Substances (S. 1561), S10484 [5AU]
———treatment of gamma y-hydroxybutyrate and ketamine hydrochloride relative to the Controlled Substances Act (H.R. 2130), S14872-S14877 [19NO]
———treatment of gamma y-hydroxybutyrate and ketamine hydrochloride relative to the Controlled Substances Act (H.R. 2130), insert S. 1561 language in lieu, S14872 [19NO]
———treatment of gamma y-hydroxybutyrate and ketamine hydrochloride relative to the Controlled Substances Act (S. 1561), S14870-S14877 [19NO]
Reports filed
Consideration of H.R. 2260, Pain Relief Promotion Act: Committee on Rules (House) (H. Res. 339) (H. Rept. 106-409), H10723 [21OC]
Date-Rape Act: Committee on Commerce (House) (H.R. 2130) (H. Rept. 106-340), H8872 [27SE]
Date-Rape Drug Control Act: Committee on the Judiciary (Senate) (S. 1561), S14805 [18NO]
Drug Addiction Treatment Act: Committee on Commerce (House) (H.R. 2634) (H. Rept. 106-441), H11480 [3NO]
Pain Relief Promotion Act: Committee on Commerce (House) (H.R. 2260) (H. Rept. 106-378), H10173 [18OC]
———Committee on the Judiciary (House) (H.R. 2260) (H. Rept. 106-378), H10032 [13OC]
Summaries
Methamphetamine Anti-Proliferation Act (S. 1428), S9091 [22JY]
Texts of
H. Res. 339, consideration of H.R. 2260, Pain Relief Promotion Act, H10868 [27OC]
H.R. 2130, Date-Rape Prevention Drug Act, H9863 [12OC]
H.R. 2260, Pain Relief Promotion Act, H10889 [27OC]
S. 324, Drug Addiction Treatment Act, S1090 [28JA]
S. 883, New Drugs of the 1990's Control Act, S4273 [27AP]
S. 1272, Pain Relief Promotion Act, S7533 [23JN]
S. 1428, Methamphetamine Anti-Proliferation Act, S9089-S9091 [22JY]
S. 1561, Date-Rape Drug Control Act, S10485 [5AU], S14870-S14872 [19NO]